AJMC: 51.3% of GLP-1 Users Now Carry an Emerging-Indication Diagnosis, OSA Leading at 25.5%
AJMC reported real-world claims data showing that 51.3% of patients on GLP-1 drugs carry at least one diagnosis tied to an emerging GLP-1 indication, 13.8% carry two, and 6.8% carry three or more. Obstructive sleep apnea led the comorbidity prevalence at 25.5%, followed by major depressive disorder at 18.2%, chronic kidney disease at 10.6%, and NAFLD/NASH at 10.3%. The numbers quantify the indication creep the field has been narrating since ADA: prescribers are increasingly writing GLP-1s for patients whose secondary conditions align with the expanding regulatory map (Wegovy CV, FLOW kidney, SURMOUNT-OSA, ESSENCE MASH).